Market research
CRDL.TO Cardiol Therapeutics Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 301M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 0.47
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA14161Y2006
- Market cap
- 301M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- Not available
- Beta
- 0.47
About
About Cardiol Therapeutics Inc
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CRDL.TO discussion.
5 years, 4 months ago
Cardiol Therapeutics Inc is currently in a long term downtrend where the price is trading 17.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cardiol Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 43.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 17.4% to $-3M since the same quarter in the previous year.
Based on the above factors, Cardiol Therapeutics Inc gets an overall score of 2/5.